Picture loading failed.

Anti-MUC5AC therapeutic antibody (Pre-made Ensituximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ensituximab (NPC-1C) is a chimeric monoclonal antibody under development for as a candidate for treatment of cancers. The target of the antibody is uncertain and is described as "human colorectal and pancreatic carcinoma-associated antigens", a set of tumor antigens isolated from human cancers. The target might be Mucin 5AC.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-187-1mg 1mg 3090
GMP-Bios-ab-187-10mg 10mg 21890
GMP-Bios-ab-187-100mg 100mg 148000
GMP-Bios-ab-187-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-MUC5AC therapeutic antibody (Pre-made Ensituximab biosimilar,Whole mAb)
INN Name Ensituximab
TargetMUC5AC
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesNeogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine
Conditions Approvedna
Conditions ActiveColorectal cancer;Pancreatic cancer
Conditions Discontinuedna
Development Techna